Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 29:9:1403-1413.
doi: 10.2147/JHC.S390858. eCollection 2022.

Development and Validation of Prognostic Nomograms for Hepatocellular Carcinoma After Hepatectomy Based on Inflammatory Markers

Zili Hu #  1   2 , Yu Yuan #  3 , Zhiwen Hu #  1   2 , Qingbo Liu  4 , Yizhen Fu  1   2 , Jingyu Hou  1   2 , Xuqi Sun  5 , Shaoqiang Li  6 , Wenbin Duan  7 , Minshan Chen  1   2
Affiliations

Development and Validation of Prognostic Nomograms for Hepatocellular Carcinoma After Hepatectomy Based on Inflammatory Markers

Zili Hu et al. J Hepatocell Carcinoma. .

Abstract

Background: The value of lactate dehydrogenase (LDH) compared with other inflammation-based scores in predicting the outcomes of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients after curative resection remains unknown. This study aims to evaluate the predictive value of LDH and develop novel nomograms to predict postoperative recurrence and survival in these patients.

Methods: This study retrospectively collected 1560 patients with HBV-related HCC who underwent curative resection from four institutions in China. In total, 924 patients were recruited from our center and randomly divided into the training cohort (n = 616) and internal validation (n = 308) cohorts. Additionally, 636 patients were selected from three other centers as the external validation cohort. The C index of inflammation-based scores was calculated and compared in the training cohort. Novel models were developed according to multivariable Cox regression analysis in the training cohort and validated in the internal and external validation cohorts.

Results: LDH showed a higher C-index than other inflammation-based scores for recurrence survival (RFS, 0.60, 95% CI, 0.58-0.61) and overall survival (OS, 0.65, 95% CI, 0.63-0.68). The nomograms of RFS and OS were developed based on tumor diameter, macrovascular invasion, AFP, operative hemorrhage, tumor differentiation, tumor number and LDH and achieved a high C-index (0.78, 95% CI, 0.76-0.79 and 0.81, 95% CI, 0.79-0.83), which were remarkably higher than the C-indexes of the five conventional HCC staging systems (0.52-0.62 for RFS and 0.53-0.67 for OS). The nomograms were validated in the internal validation cohort (0.77 for RFS, 0.78 for OS) and external validation cohort (0.80 for RFS, 0.81 for OS) and performed well-fitted calibration curves.

Conclusion: The two nomograms based on inflammatory markers achieved optimal prediction for RFS and OS of patients with HBV-related HCC after hepatectomy.

Keywords: hepatectomy; hepatocellular carcinoma; inflammation-based scores; lactate dehydrogenase; nomogram.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare in this work.

Figures

Figure 1
Figure 1
Time-dependent AUC (area under ROC curve) plot for recurrence-free survival (A) and overall survival (B) prediction of inflammation-based scores.
Figure 2
Figure 2
Nomograms for predicting the 1-, 3- and 5-year recurrence (A) and mortality (B) rates in patients with hepatitis B virus-related hepatocellular carcinoma.
Figure 3
Figure 3
The calibration curves for predicting the 1-, 3- and 5-year recurrence in the training cohort (A), internal validation cohort (C) and external validation cohorts (E) and the calibration curves for predicting the 1-, 3- and 5-year mortality in the training cohort (B), internal validation cohort (D) and external validation cohorts (F).
Figure 4
Figure 4
Kaplan-Meier survival curves for subgroups of patients estimating recurrence-free survival in the training cohort (A), internal validation cohort (B) and external validation cohort (C) and overall survival in the training cohort (D), internal validation cohort (E) and external validation cohort (F).
See this image and copyright information in PMC

References

    1. Akinyemiju T, Abera S, Ahmed M., et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level results from the Global Burden of Disease Study 2015. JAMA Oncology. 2017;3(12):1683–1691. doi:10.1001/jamaoncol.2017.3055 - DOI - PMC - PubMed
    1. Fitzmaurice C, Abate D, Abbasi N, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017 a systematic analysis for the Global Burden of Disease Study. JAMA Oncology. 2019;5(12):1749–1768. doi:10.1001/jamaoncol.2019.2996 - DOI - PMC - PubMed
    1. Vos T, Abajobir AA, Abate KH. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–1259. doi:10.1016/S0140-6736(17)32154-2 - DOI - PMC - PubMed
    1. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–1474. doi:10.1245/s10434-010-0985-4 - DOI - PubMed
    1. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30(1):61–74. doi:10.1055/s-0030-1247133 - DOI - PubMed